Q1 Earnings Forecast for VKTX Issued By HC Wainwright

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Viking Therapeutics in a research report issued to clients and investors on Thursday, February 6th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of ($0.26) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $102.00 price objective on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Viking Therapeutics' Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.51) EPS.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.05). During the same quarter last year, the business earned ($0.25) EPS.

Other equities analysts have also recently issued reports about the company. Maxim Group reduced their target price on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. B. Riley reaffirmed a "buy" rating and set a $96.00 target price (down from $109.00) on shares of Viking Therapeutics in a research report on Friday, February 7th. William Blair reaffirmed an "outperform" rating on shares of Viking Therapeutics in a research report on Wednesday, November 20th. Raymond James boosted their price target on Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Finally, Piper Sandler lowered their price target on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Viking Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.29.

Viking Therapeutics Stock Up 0.6 %

VKTX traded up $0.18 during trading hours on Monday, hitting $29.50. The stock had a trading volume of 3,663,468 shares, compared to its average volume of 4,034,338. The stock has a market cap of $3.29 billion, a PE ratio of -29.50 and a beta of 0.90. Viking Therapeutics has a 1 year low of $28.64 and a 1 year high of $99.41. The company's fifty day simple moving average is $38.38 and its 200 day simple moving average is $53.09.

Institutional Investors Weigh In On Viking Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Oak Ridge Investments LLC acquired a new stake in Viking Therapeutics during the 3rd quarter worth approximately $837,000. Oppenheimer & Co. Inc. increased its stake in Viking Therapeutics by 43.5% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 102,324 shares of the biotechnology company's stock valued at $6,478,000 after purchasing an additional 31,011 shares in the last quarter. Nvwm LLC bought a new stake in Viking Therapeutics during the 3rd quarter valued at $999,000. Chartwell Investment Partners LLC increased its stake in Viking Therapeutics by 88.0% during the 3rd quarter. Chartwell Investment Partners LLC now owns 36,666 shares of the biotechnology company's stock valued at $2,322,000 after purchasing an additional 17,159 shares in the last quarter. Finally, Stifel Financial Corp grew its stake in shares of Viking Therapeutics by 92.1% in the 3rd quarter. Stifel Financial Corp now owns 131,348 shares of the biotechnology company's stock worth $8,316,000 after acquiring an additional 62,956 shares in the last quarter. 76.03% of the stock is owned by institutional investors.

Insider Transactions at Viking Therapeutics

In other news, CEO Brian Lian sold 194,490 shares of the firm's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the completion of the sale, the chief executive officer now owns 2,366,570 shares in the company, valued at approximately $101,170,867.50. This trade represents a 7.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Marianna Mancini sold 54,215 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the completion of the sale, the chief operating officer now owns 374,134 shares of the company's stock, valued at $15,994,228.50. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 299,014 shares of company stock worth $12,782,849. 4.70% of the stock is currently owned by company insiders.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.